VFA
TCRT icon

Virtus Fund Advisers’s Alaunos Therapeutics TCRT Stock Holding History

Virtus Fund Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$338K Buy
+545
New +$392K ﹤0.01% 423
2014
Q3 		– Sell
-46
Closed -$28K – 1857
2014
Q2 		$28K Buy
+46
New +$25.6K ﹤0.01% 2247

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus Fund Advisers's TCRT Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Alaunos Therapeutics (TCRT) in Q4 2017: 545 shares worth $338K. The stake represents ﹤0.01% of the portfolio and ranks #423 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in TCRT as recently as Q2 2014.

Virtus Fund Advisers first reported a position in TCRT in Q2 2014 and has held it in 2 quarters since. 128 funds tracked by Wall St. Rank hold TCRT as of Q4 2017.

  • Virtus Fund Advisers held 545 shares of Alaunos Therapeutics worth $338K as of Q4 2017.
  • Alaunos Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Alaunos Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #423 holding.
  • Virtus Fund Advisers first reported a position in Alaunos Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.